非小细胞肺癌：新辅助化免治疗 vs 新辅助化疗：系统评价和Meta分析

新辅助化疗免疫治疗在手术、病理和疗效结果方面优于新辅助化疗，并且无事件生存期均得到改善，对于可切除NSCLC患者，尤其是PD-L1表达小于1%的患者，新辅助化疗免疫治疗在无事件生存期方面展现出优势，新辅助化疗免疫治疗在手术切除率和R0切除率方面优于化疗

Zhang Q, Duan J, Zhang Y, Yang L, Li D. Perioperative or neo/adjuvant chemoimmunotherapy versus chemotherapy for resectable non-small cell lung cancer: a systematic review and network meta-analysis. Syst Rev. 2025 Jan 24;14(1):24. doi: 10.1186/s13643-025-02767-6. PMID: 39856765; PMCID: PMC11760710.
Perioperative or neo/adjuvant chemoimmunotherapy versus chemotherapy for resectable non-small cell lung cancer: a systematic review and network meta-analysis | Systematic Reviews | Springer Nature Link

Sorin M, Prosty C, Ghaleb L, et al. Neoadjuvant Chemoimmunotherapy for NSCLC: A Systematic Review and Meta-Analysis. JAMA Oncol. 2024;10(5):621–633. doi:10.1001/jamaoncol.2024.0057
Neoadjuvant Chemoimmunotherapy for NSCLC: A Systematic Review and Meta-Analysis | Cancer Biomarkers | JAMA Oncology | JAMA Network